Independent Advisor Alliance Purchases 3,816 Shares of Biogen Inc. $BIIB

Independent Advisor Alliance boosted its position in Biogen Inc. (NASDAQ:BIIB) by 175.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,987 shares of the biotechnology company’s stock after acquiring an additional 3,816 shares during the quarter. Independent Advisor Alliance’s holdings in Biogen were worth $1,054,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. World Investment Advisors grew its stake in shares of Biogen by 4.9% during the fourth quarter. World Investment Advisors now owns 6,739 shares of the biotechnology company’s stock worth $1,155,000 after buying an additional 317 shares during the last quarter. AG2R LA Mondiale Gestion D Actifs bought a new stake in shares of Biogen during the fourth quarter worth $1,454,000. Valeo Financial Advisors LLC bought a new stake in shares of Biogen during the fourth quarter worth $211,000. Colonial River Investments LLC bought a new stake in shares of Biogen during the fourth quarter worth $400,000. Finally, Pure Financial Advisors LLC bought a new stake in shares of Biogen during the fourth quarter worth $206,000. 87.93% of the stock is owned by institutional investors.

Biogen Stock Performance

Shares of Biogen stock opened at $192.95 on Friday. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. Biogen Inc. has a twelve month low of $121.05 and a twelve month high of $205.97. The stock has a market cap of $28.49 billion, a price-to-earnings ratio of 20.70, a P/E/G ratio of 1.68 and a beta of 0.19. The company’s fifty day moving average is $185.21 and its 200 day moving average is $179.33.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping the consensus estimate of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter in the previous year, the firm posted $3.02 earnings per share. Biogen’s revenue for the quarter was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Sell-side analysts forecast that Biogen Inc. will post 14.21 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Rothschild & Co Redburn boosted their target price on shares of Biogen from $180.00 to $190.00 in a research note on Thursday, April 30th. Weiss Ratings raised shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 1st. The Goldman Sachs Group boosted their target price on shares of Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Sanford C. Bernstein decreased their target price on shares of Biogen from $201.00 to $200.00 in a research note on Thursday, April 30th. Finally, Royal Bank Of Canada boosted their target price on shares of Biogen from $213.00 to $222.00 and gave the stock an “outperform” rating in a research note on Thursday, April 30th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $215.62.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen said its Phase 2 CELIA study of diranersen (BIIB080), a tau-targeting Alzheimer’s drug, showed robust reductions in tau pathology and signals of slowed cognitive decline, prompting the company to advance the program into late-stage development. Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
• Positive Sentiment: Goldman Sachs reiterated a Buy rating and lifted its price target to $250, while Oppenheimer raised its target to $300 and Evercore initiated coverage with an Outperform rating, reinforcing optimism around Biogen’s valuation and pipeline. Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250 Oppenheimer raises Biogen price target to $300 from $275, maintains Outperform rating
• Positive Sentiment: Biogen completed its $5.3 billion acquisition of Apellis Pharmaceuticals, adding commercial products SYFOVRE and EMPAVELI and potentially improving near-term growth prospects. Biogen Completes Acquisition of Apellis Pharmaceuticals
• Neutral Sentiment: Some analysts remain cautious, saying mixed Alzheimer’s data and pipeline uncertainty still create a balanced risk/reward profile despite the recent rally. Biogen: Hold Rating Reiterated as Pipeline Concerns Offset Leqembi Growth; $196 Price Target Maintained
• Negative Sentiment: The CELIA study missed its primary endpoint, and a law firm has already announced an investigation into possible securities-law issues tied to the stock’s move after the data release, which could add headline risk. Investigation Alert: Biogen Inc. (BIIB) Under Scrutiny – Contact Levi & Korsinsky for Details

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.